Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
Dan J SiskindMargaret K HahnChristoph U CorrellAnders Fink-JensenAnthony W RussellNikolaj BakBrian V BrobergJulie LarsenPelle L IshøyTina VilsbøllFilip K KnopMeshary Khaled N AlotibyBjørn H EbdrupPublished in: Diabetes, obesity & metabolism (2018)
GLP-1RAs are effective and tolerable for antipsychotic-associated body weight gain, particularly clozapine/olanzapine-treated patients. With few included patients, further studies are required before making routine use recommendations for GLP-1RAs.
Keyphrases
- weight gain
- risk factors
- systematic review
- end stage renal disease
- newly diagnosed
- body mass index
- ejection fraction
- clinical practice
- birth weight
- chronic kidney disease
- case control
- wild type
- peritoneal dialysis
- randomized controlled trial
- electronic health record
- weight loss
- meta analyses
- machine learning
- physical activity